Latest Ratios: P/E Ratio -7.5x · EV/EBITDA N/A · ROE -132.6%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $69M | $91M | $134M | — | — | — |
| Enterprise Value | $67M | $90M | $126M | — | — | — |
| P/E Ratio → | -7.47 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 20.08 | 26.89 | 12.87 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -132.6% | -132.6% | -116.8% | -412.5% | -108.7% | -101.0% |
| ROA | -96.4% | -96.4% | -70.6% | -65.3% | -55.5% | -51.5% |
| ROIC | -395.0% | -395.0% | -273.9% | -104.3% | -71.6% | — |
| ROCE | -120.7% | -120.7% | -92.4% | -112.5% | -66.7% | -66.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.13 | — | 0.44 | 0.60 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.53 | -0.80 | — | 0.04 | 0.14 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($3M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.51 | 2.51 | 8.12 | 0.50 | 2.32 | 2.61 |
| Quick Ratio | 2.51 | 2.51 | 8.12 | 0.50 | 2.32 | 2.61 |
| Cash Ratio | 1.94 | 1.94 | 7.29 | 0.03 | 0.88 | 1.37 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $8M | $8M | $8M | $8M | $8M |
Imminent liquidity exhaustion
As reported in financial statements, EXOZ trades at a price-to-book ratio of 19.81, a figure that appears disconnected from fundamental value given the company's persistent lack of revenue and the ongoing erosion of its equity base over the last ten quarters.
The elevated P/B ratio suggests that the market is pricing the firm as a speculative call option on its intellectual property rather than a going concern with tangible assets. Investors should monitor whether this valuation can be sustained as the company's book value continues to decline due to persistent net losses.
Based on the company's reported figures, the ROIC has remained deeply negative, reaching -125.6% in 2026Q1, which indicates that the firm is currently destroying shareholder capital at an accelerating rate while failing to achieve the commercial milestones necessary to justify its R&D expenditures.
The consistent inability to generate positive returns on invested capital suggests that the SimplePath platform has yet to reach a stage of economic viability. This trend warrants further investigation into whether the current R&D strategy can ever produce a positive return profile or if the business model is structurally flawed.
According to recent SEC filings, the current ratio has compressed to 1.32 as of 2026Q1, a significant decline from the 8.12 observed in 2024Q4, which suggests that the company's ability to meet short-term obligations is becoming increasingly constrained by its rapid cash burn.
The rapid deterioration of the current ratio indicates that the firm is consuming its liquid assets faster than it can replenish them through financing. This liquidity profile appears highly vulnerable, and investors should monitor the potential for near-term dilutive capital raises to maintain basic operations.
While the price-to-book ratio is frequently used to assess value in industrial firms, it remains a misleading metric for EXOZ, as the company's book value is primarily composed of R&D-related assets that may hold little liquidation value in the event of a commercial failure.
Analysts should instead focus on the cash runway and the burn rate, as these metrics provide a more accurate reflection of the firm's survival probability. Relying on book value obscures the reality that the company's primary assets are intangible and highly dependent on future, unproven commercial success.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EXOZ stock.
eXoZymes, Inc.'s current P/E ratio is -7.5x. This places it at the 50th percentile of its historical range.
eXoZymes, Inc.'s return on equity (ROE) is -132.6%. The historical average is -174.3%.
Based on historical data, eXoZymes, Inc. is trading at a P/E of -7.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.